{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T16:51:45Z","timestamp":1782924705489,"version":"3.54.5"},"reference-count":30,"publisher":"Japanese Society of Internal Medicine","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,10,15]]},"DOI":"10.2169\/internalmedicine.4774-24","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T18:07:19Z","timestamp":1745863639000},"page":"3020-3026","source":"Crossref","is-referenced-by-count":2,"title":["Successful Salvage Therapy with Pomalidomide, Cyclophosphamide, and Dexamethasone for IgM Myeloma with t (11;14) and Dim CD38 Expression Refractory to Daratumumab, Lenalidomide, and Dexamethasone"],"prefix":"10.2169","volume":"64","author":[{"given":"Takashi","family":"Fujishima","sequence":"first","affiliation":[{"name":"Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Japan"},{"name":"Department of Hematology, Nephrology and Rheumatology, Noshiro Kousei Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isuzu","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Kitadate","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Kameoka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Akita Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78: 21-33, 2003.","DOI":"10.4065\/78.1.21"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Bazarbachi AH, Avet-Loiseau H, Szalat R, et al. IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM. Blood 138: 1980-1985, 2021.","DOI":"10.1182\/blood.2021011452"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Facon T, Kumar SK, Plesner T, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol 22: 1582-1596, 2021.","DOI":"10.1016\/S1470-2045(21)00466-6"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15: e538-548, 2014.","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Xu L, Hunter ZR, Yang G, et al. MYD88 L265P in Waldenstrom&apos;s macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood 121: 2051-2058, 2013.","DOI":"10.1182\/blood-2012-09-454355"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. King RL, Howard MT, Hodnefield JM, Morice WG. IgM multiple myeloma: pathologic evaluation of a rare entity. Am J Clin Pathol 140: 519-524, 2013.","DOI":"10.1309\/AJCP0N7IELYUNJGZ"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Avet-Loiseau H, Garand R, Lod\u00e9 L, Harousseau JL, Bataille R; Intergroupe Francophone du My\u00e9lome. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants, Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood 101: 1570-1571, 2003.","DOI":"10.1182\/blood-2002-08-2436"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Feyler S, O&apos;Connor SJ, Rawstron AC, et al. IgM myeloma: a rare entity characterized by a CD20-CD56-CD117- immunophenotype and the t(11;14). Br J Haematol 140: 547-551, 2008.","DOI":"10.1111\/j.1365-2141.2007.06969.x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Castillo JJ, Jurczyszyn A, Brozova L, et al. IgM myeloma: a multicenter retrospective study of 134 patients. Am J Hematol 92: 746-751, 2017.","DOI":"10.1002\/ajh.24753"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 121: 482-488, 2004.","DOI":"10.1309\/74R4TB90BUWH27JX"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Angelova EA, Li S, Wang W, et al. IgM plasma cell myeloma in the era of novel therapy: a clinicopathological study of 17 cases. Hum Pathol 84: 321-334, 2019.","DOI":"10.1016\/j.humpath.2018.09.008"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Mina R, Bonello F, Gay F, Zamagni E, Boccadoro M. Daratumumab-based therapy for IgM multiple myeloma with hyperviscosity syndrome: a case report. Clin Lymphoma Myeloma Leuk 21: e21-e24, 2021.","DOI":"10.1016\/j.clml.2020.08.019"},{"key":"13","unstructured":"13. Chhabra S, Jain S, Fowler A, et al. IgM myeloma with plasma cell leukemia: case report and literature review. Ann Clin Lab Sci 47: 611-619, 2017."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Hoyer JD, Hanson CA, Fonseca R, Greipp PR, Dewald GW, Kurtin PJ. The (11;14) (q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study. Am J Clin Pathol 113: 831-837, 2000.","DOI":"10.1309\/4W8E-8F4K-BHUP-UBE7"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Garand R, Avet-Loiseau H, Accard F, Moreau P, Harousseau JL, Bataille R. t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma. Leukemia 17: 2032-2035, 2003.","DOI":"10.1038\/sj.leu.2403091"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kitadate A, Terao T, Narita K, et al. Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence. Cancer Sci 112: 3645-3654, 2021.","DOI":"10.1111\/cas.15073"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Nikesitch N, Lee JM, Ling S, Roberts TL. Endoplasmic reticulum stress in the development of multiple myeloma and drug resistance. Clin Transl Immunol 7: e1007, 2018.","DOI":"10.1002\/cti2.1007"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Puertas B, Gonzalez-Calle V, Sobehano-Fuertes E, et al. Multiple myeloma with t(11;14): impact of novel agents on outcome. Blood Cancer J 13: 40, 2023.","DOI":"10.1038\/s41408-023-00807-9"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Gazitt Y, Fey V, Thomas C, Alvarez R. Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells. Int J Oncol 13: 397-405, 1998.","DOI":"10.3892\/ijo.13.2.397"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Takamatsu H, Yamashita T, Kurahashi S, et al. Clinical implications of t(11;14) in patients with multiple myeloma undergoing autologous stem cell transplantation. Biol Blood Marrow Transplant 25: 474-479, 2019.","DOI":"10.1016\/j.bbmt.2018.11.003"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Rychak E, Mendy D, Shi T, et al. Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma. Br J Haematol. 172: 889-901, 2016.","DOI":"10.1111\/bjh.13905"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Baz RC, Martin TG 3rd, Lin HY, et al. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood 127: 2561-2568, 2016.","DOI":"10.1182\/blood-2015-11-682518"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105: 1045-1047, 2000.","DOI":"10.1172\/JCI9872"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4: 423-436, 2004.","DOI":"10.1038\/nrc1369"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Le DT, Jaffee EM. Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res 72: 3439-3444, 2012.","DOI":"10.1158\/0008-5472.CAN-11-3912"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Zhao J, Cao Y, Lei Z, Yang Z, Zhang B, Huang B. Selective depletion of CD4<sup>+<\/sup>CD25<sup>+<\/sup>Foxp3<sup>+<\/sup> regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. Cancer Res 70: 4850-4858, 2010.","DOI":"10.1158\/0008-5472.CAN-10-0283"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Franssen LE, Nijhof IS, Bjorklund CC, et al. Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients. Oncotarget 9: 34009-34021, 2018.","DOI":"10.18632\/oncotarget.26131"},{"key":"28","doi-asserted-by":"publisher","unstructured":"28. Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38<sup>+<\/sup> immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 128: 384-394, 2016.","DOI":"10.1182\/blood-2015-12-687749"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Frerichs KA, Broekmans MEC, Marin Soto JA, van Kessel B, Heymans MW, Holthof LC, et al. Preclinical activity of JNJ-7957, a novel BCMA\u00d7CD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab. Clin Cancer Res 26: 2203-2215, 2020.","DOI":"10.1158\/1078-0432.CCR-19-2299"},{"key":"30","doi-asserted-by":"publisher","unstructured":"30. Walker BA, Wardell CP, Johnson DC, et al. Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood 121: 3413-3419, 2013.","DOI":"10.1182\/blood-2012-12-471888"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/20\/64_4774-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T04:26:29Z","timestamp":1760761589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/20\/64_4774-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":30,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4774-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"article-number":"4774-24"}}